August 2007 Supplement Research Papers

• August 21

  • A probiotic lozenge administered medical device and its effect on salivary mutans streptococci and lactobacilli.

    • 2007-08-21
    • RCT · n = 20
    • International Journal of Paediatric Dentistry 18(1)
    • • E. Çaglar
      • O. Kuscu
      • S. Cildir
      • Senem Selui Kuvvetli
      • N. Sandalli

    • PubMed: 18086024
    • DOI: 10.1111/J.1365-263X.2007.00866.X

    1 Insight on

    • Reduced Salivary Levels of Mutans Streptococci

    • High evidence
    • Highly Cited
• Undated – 2 supplement studies

  • Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats.

    • 2007-08
    • Clinical Trial
    • The Journal of Nutrition 137(8)
    • • H. Eutamene
      • Florence Lamine
      • C. Chabo
      • V. Théodorou
      • F. Rochat
      • G. Bergonzelli
      • I. Corthésy-theulaz
      • J. Fioramonti
      • L. Buéno

    • PubMed: 17634262
    • DOI: 10.1093/JN/137.8.1901

    5 Insights on

    • Improved Epithelial Permeability
    • Improved Gut Permeability
    • Reduced Visceral Pain
    • Reduced Stress-Mediated Visceral Hyperalgesia
    • Prevented Visceral Hyperalgesia

    • Low evidence
    • Highly Cited
    • Animal Study

  • Safety assessment of the human milk-isolated probiotic Lactobacillus salivarius CECT5713.

    • 2007-08
    • RCT · n = 50
    • Journal of Dairy Science 90(8)
    • • F. Lara‐Villoslada
      • S. Sierra
      • M. Díaz-Ropero
      • M. Olivares
      • J. Xaus

    • PubMed: 17638967
    • DOI: 10.3168/JDS.2006-685

    20 Insights on

    • No Adverse Effects on Body Weight or Food Intake
    • Absence of Treatment-Associated Bacterial Translocation
    • Significant Bacterial Translocation with Intraperitoneal Administration
    • Increased Plasma Serum Alpha-Amyloid Protein
    • Nonpathogenic Even at High Doses
    • Ensured Safety for Human Consumption
    • Reduced Bacterial Translocation
    • Absence of Bacteremia
    • No Hepatic or Splenic Translocation with Oral Administration
    • No Illness or Death Despite Bacterial Translocation
    • Nonpathogenic Condition
    • No Bacteremia or Translocation of Bacteria to Vital Organs
    • Absence of Bacterial Translocation to Liver or Spleen
    • No Illness or Death from Bacterial Translocation (Intraperitoneal Administration)
    • No Bacteremia
    • No Adverse Weight or Intake Effects in Mice
    • Nonpathogenic for Mice
    • Maintained Body Weight
    • No Adverse Effects from Intraperitoneal Administration
    • Increased Serum Amyloid Protein

    • Low evidence
    • Animal Study